(-)-epigallocatechin 3-gallate/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Inhibits EPHB2
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“Western blot analysis confirmed diminished ERK activity in the EGCG-treated arteries, with a diminished phospho:total ERK ratio in the EGCG-treated arteries (P=.036, Mann-Whitney U test; Figure 4).”
Quoted verbatim from Epigallocatechin-3-gallate is a potent phytochemical inhibitor of intimal hyperplasia in the wire-injured carotid artery.. - Study
- animal · not in humans
- Duration
- 14 days
- Dose
- 1 mg/kg EGCG intraperitoneally daily from one day before surgery
- Population
- Wire-injured common carotid arteries of male Sprague-Dawley rats given daily intraperitoneal EGCG versus saline, harvested at 2 weeks
Epigallocatechin-3-gallate is a potent phytochemical inhibitor of intimal hyperplasia in the wire-injured carotid artery.2013PMID:23538007Permalink
Keep reading
- Everything the graph holds on (-)-epigallocatechin 3-gallate
- Every compound studied against EPHB2
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45SNRZ4FKM724DXQAWN1PSS